Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Redirected Auto T Cells for Advanced Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Adaptimmune
Sponsor:
Collaborators:
University of Maryland Greenebaum Cancer Center
Abramson Cancer Center of the University of Pennsylvania
Information provided by (Responsible Party):
Adaptimmune
ClinicalTrials.gov Identifier:
NCT01352286
First received: May 4, 2011
Last updated: October 30, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2031
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)